Department of Infectious Diseases, Prince of Wales Hospital, Randwick, NSW, Australia.
Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology - Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia.
Pathology. 2020 Dec;52(7):745-753. doi: 10.1016/j.pathol.2020.09.011. Epub 2020 Oct 8.
The first laboratory confirmed case of Coronavirus disease 2019 (COVID-19) in Australia was in Victoria on 25 January 2020 in a man returning from Wuhan city, Hubei province, the People's Republic of China. This was followed by three cases in New South Wales the following day. The Australian Government activated the Australian Health Sector Emergency Response Plan for Novel Coronavirus on 27 February 2020 in anticipation of a pandemic. Subsequently, the World Health Organization declared COVID-19 to be a Public Health Emergency of International Concern followed by a pandemic on 30 January 2020 and 11 March 2020, respectively. Laboratory testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, is key in identifying infected persons to guide timely public health actions of contact tracing and patient isolation to limit transmission of infection. This article aims to provide a comprehensive overview of current laboratory diagnostic methods for SARS-CoV-2, including nucleic acid testing, serology, rapid antigen detection and antibody tests, virus isolation and whole genome sequencing. The relative advantages and disadvantages of the different diagnostic tests are presented, as well as their value in different clinical, infection control and public health contexts. We also describe the challenges in the provision of SARS-CoV-2 diagnostics in Australia, a country with a relatively low COVID-19 incidence in the first pandemic wave but in which prevalence could rapidly change.
澳大利亚首例 2019 年冠状病毒病(COVID-19)实验室确诊病例于 2020 年 1 月 25 日在维多利亚州出现,患者为一名从中国湖北省武汉市返回的男子。次日,新南威尔士州又报告了三例病例。澳大利亚政府于 2020 年 2 月 27 日启动了澳大利亚卫生部门新发冠状病毒应急计划,以应对大流行。随后,世界卫生组织于 2020 年 1 月 30 日和 3 月 11 日分别宣布 COVID-19为国际关注的突发公共卫生事件和大流行。针对导致 COVID-19 的严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的实验室检测是识别感染者的关键,以便及时采取公共卫生措施进行接触者追踪和患者隔离,以限制感染传播。本文旨在全面概述 SARS-CoV-2 的当前实验室诊断方法,包括核酸检测、血清学检测、快速抗原检测和抗体检测、病毒分离和全基因组测序。介绍了不同诊断检测方法的相对优缺点,以及它们在不同临床、感染控制和公共卫生背景下的价值。我们还描述了澳大利亚在提供 SARS-CoV-2 诊断方面面临的挑战,澳大利亚在第一波大流行期间 COVID-19 发病率相对较低,但流行率可能会迅速变化。